Decibel Cannabis Company Inc. DB DBCCF announced its unaudited interim financial results on Thursday for the third quarter ending Sept. 30, 2024.
“Decibel has been very deliberate about reducing our current liabilities, by ~5mm this quarter," CEO Benjamin Sze said. "Maintaining discipline over time will result in a stronger balance sheet. This marks the last quarter where our primary focus is on Canadian domestic recreational sales. While we continue to integrate AgMedica into our portfolio, it is encouraging to see significant demand internationally for Decibel flower.”
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
Q3 Financial Highlights
- Net revenue totaled CA$24.1 million ($17.2 million), representing a 9% increase sequentially, but a 12% decrease year-over-year.
- Gross profit before fair value adjustments was CA$12.7 million, compared to roughly CA$12 million in the prior year's period.
- Gross margin before fair value adjustments reached 53% in the third quarter, up from 44% in the prior year's period, reflecting improved operational efficiency.
- Adjusted EBITDA was positive at CA$5.1 million, representing a 31% increase from the previous quarter but a 21% decrease year over year.
- Net loss and comprehensive loss amounted to CA$585 000, compared to a net income and comprehensive income of CA$413 000.
- Generated positive free cash flow of $1.8 million, up 75% year-over-year.
The company said that it's seeing significant demand for its flower internationally as it continues to integrate AgMedica.
Decibel closed the acquisition of AgMedica Bioscience Ltd. in October. The transaction was arranged through an agreement with Callisto Capital Corp. and was made in exchange for a $6.3 million unsecured convertible debenture.
Read Next:
DBCCF Price Action
Decibel's shares traded 5.54% higher at $0.0495 per share after the market close on Thursday afternoon.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.